Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 5.8% After Analyst Upgrade

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s share price was up 5.8% on Friday after Jefferies Financial Group raised their price target on the stock from $54.00 to $58.00. Jefferies Financial Group currently has a buy rating on the stock. Tarsus Pharmaceuticals traded as high as $44.97 and last traded at $46.08. Approximately 23,253 shares changed hands during trading, a decline of 96% from the average daily volume of 638,316 shares. The stock had previously closed at $43.57.

Several other brokerages also recently issued reports on TARS. The Goldman Sachs Group lifted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. Oppenheimer lifted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Barclays cut their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $63.67.

Remove Ads

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Crowley Wealth Management Inc. acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $44,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. Quarry LP acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $166,000. Finally, HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $207,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Performance

The firm's 50-day moving average price is $49.97 and its 200 day moving average price is $43.88. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -12.20 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analysts' expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.